Bicara Therapeutics Inc. (BCAX)
NGM · Healthcare · Biotechnology
$21.69
+1.93%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.43B
Shares Outstanding
65.7M
Exchange
NGM
Currency
USD
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -32.0M | -40.7M | -41.1M | -60.2M |
| Net Income | -27.4M | -36.3M | -37.4M | -56.2M |
| Diluted EPS | $-0.50 | $-0.67 | $-0.68 | $-0.93 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -37.7M | -39.9M | -82.4M | -155.6M |
| Net Income | -37.8M | -52.0M | -68.0M | -137.9M |
| Diluted EPS | $-2.45 | $-1.53 | $-4.05 | $-2.52 |